Market Overview

Teva Says Positive Phase 3 Results on Quartette

Share:
Related TEVA
Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches
Mylan Inks Deal With Mapi Pharma For Multiple Sclerosis Drug
The European Central Bank Updates, And The EU Monitors Imports (Wall Street Breakfast Podcast) (Seeking Alpha)

Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced the findings from a Phase III pivotal trial of QuartetteTM (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets), an investigational ascending-dose, extended-regimen oral contraceptive for the prevention of pregnancy that is currently under review by the U.S. Food and Drug Administration. These data were presented for the first time as a poster at the 68th Annual Meeting of the American Society of Reproductive Medicine (ASRM).

The Phase III, multicenter, open-label, single arm study evaluated the efficacy and safety of QuartetteTM over one year; 3,701 sexually active women 18 to 40 years old were enrolled and 2,144 completed the study. Data demonstrated QuartetteTM is efficacious for the prevention of pregnancy and has a safety profile similar to that of other oral contraceptives.1

Posted-In: News FDA

 

Related Articles (TEVA)

View Comments and Join the Discussion!